Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Zoetis Inc. (NYSE:ZTS). In a filing disclosed on September 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Zoetis stock on August 5th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.
Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):
- Purchased $1,001 - $15,000 in shares of Semtech NASDAQ: SMTC on 9/2/2025.
- Sold $1,001 - $15,000 in shares of Chart Industries NYSE: GTLS on 9/2/2025.
- Purchased $1,001 - $15,000 in shares of Avient NYSE: AVNT on 9/2/2025.
- Sold $1,001 - $15,000 in shares of Amdocs NASDAQ: DOX on 8/27/2025.
- Sold $1,001 - $15,000 in shares of Amdocs NASDAQ: DOX on 8/26/2025.
- Purchased $1,001 - $15,000 in shares of Intapp NASDAQ: INTA on 8/26/2025.
- Purchased $1,001 - $15,000 in shares of APi Group NYSE: APG on 8/26/2025.
- Purchased $1,001 - $15,000 in shares of Waters NYSE: WAT on 8/26/2025.
- Purchased $1,001 - $15,000 in shares of Semtech NASDAQ: SMTC on 8/26/2025.
- Sold $1,001 - $15,000 in shares of Fortive NYSE: FTV on 8/26/2025.
Zoetis Stock Performance
ZTS stock traded down $1.28 during midday trading on Friday, hitting $145.82. 4,455,824 shares of the stock traded hands, compared to its average volume of 2,273,605. The firm has a market cap of $64.63 billion, a P/E ratio of 25.10, a PEG ratio of 2.36 and a beta of 0.89. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The stock's fifty day simple moving average is $151.25 and its 200-day simple moving average is $156.59. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $197.51.
Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. During the same quarter last year, the business earned $1.56 earnings per share. The company's revenue for the quarter was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently issued reports on the stock. Argus reissued a "buy" rating and issued a $190.00 price target on shares of Zoetis in a research note on Tuesday, September 9th. Leerink Partnrs cut shares of Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Leerink Partners cut shares of Zoetis from an "outperform" rating to a "market perform" rating and lowered their price target for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Piper Sandler boosted their price target on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a report on Monday, August 11th. Finally, Stifel Nicolaus cut shares of Zoetis from a "buy" rating to a "hold" rating and lowered their price target for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Five research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $200.88.
Read Our Latest Report on Zoetis
Institutional Trading of Zoetis
Several institutional investors and hedge funds have recently bought and sold shares of the business. Lindbrook Capital LLC boosted its stake in Zoetis by 1.8% during the first quarter. Lindbrook Capital LLC now owns 3,715 shares of the company's stock worth $612,000 after buying an additional 65 shares in the last quarter. Scott & Selber Inc. boosted its stake in shares of Zoetis by 0.6% in the 2nd quarter. Scott & Selber Inc. now owns 11,652 shares of the company's stock valued at $1,817,000 after purchasing an additional 67 shares in the last quarter. North Star Asset Management Inc. boosted its stake in shares of Zoetis by 4.9% in the 2nd quarter. North Star Asset Management Inc. now owns 1,441 shares of the company's stock valued at $225,000 after purchasing an additional 67 shares in the last quarter. Secure Asset Management LLC boosted its stake in shares of Zoetis by 2.9% in the 2nd quarter. Secure Asset Management LLC now owns 2,448 shares of the company's stock valued at $382,000 after purchasing an additional 68 shares in the last quarter. Finally, Quotient Wealth Partners LLC boosted its stake in shares of Zoetis by 2.3% in the 1st quarter. Quotient Wealth Partners LLC now owns 3,167 shares of the company's stock valued at $521,000 after purchasing an additional 72 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.
About Representative Cisneros
Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election.
Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.
About Zoetis
(
Get Free Report)
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Featured Stories
Before you consider Zoetis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.
While Zoetis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.